Ignacio I. Wistuba
Dartmouth College, The University of Texas MD Anderson Cancer Center
Papers
3
Total Citations
88
H-Index
3
About
Ignacio I. Wistuba is a leading translational researcher whose work bridges the molecular biology of lung cancer with clinical applications. His primary research areas include the mechanisms of cell cycle dysregulation, particularly the role of CDK inhibitors in inducing anaphase catastrophe, and the use of liquid biopsies for real-time cancer monitoring. A major contribution is his investigation of next-generation CDK2/9 inhibitors, such as CCT68127, which trigger multipolar anaphase and apoptosis in lung cancer cells with supernumerary centrosomes—a novel therapeutic strategy distinct from traditional apoptosis. This work, published in 2016 (49 citations), has informed targeted therapy development. More recently, his study on dynamic circulating tumor DNA (ctDNA) response to neoadjuvant atezolizumab in NSCLC (2021, 35 citations) demonstrates his impact on immunotherapy and precision oncology, showing how ctDNA can predict treatment outcomes. He also co-authored the comprehensive *Handbook of Lung Cancer and Other Thoracic Malignancies* (2016), a key resource for clinicians and researchers. With a career focused on translating mechanistic insights into clinical biomarkers and therapies, Wistuba’s work continues to shape the landscape of lung cancer research.
Research Focus
Key Achievements
Top Papers
- 1Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer49 citations · 2016
- 2
- 3Handbook of Lung Cancer and Other Thoracic Malignancies4 citations · 2016